Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World's First Fully Recoverable Self-Expanding Dry-Valve TAVR System

Contributed by: PR Newswire

Tags

VenusMedtech-TAVR

More Like This

PR Newswire associated0

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

PR Newswire associated0

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

PR Newswire associated0

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

PR Newswire associated0

Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

Venus Medtech Hosts Inaugural Global Partner Summit in Paris